Overview

• GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are reshaping weight loss trends, with over 26% of Americans reportedly planning to use them for weight management in 2025.
• Despite their effectiveness, users often face stigma, with many keeping their usage secret due to fears of being judged for taking the 'easy way out.'
• The rise of GLP-1s is driving significant changes across industries, including food, fashion, and wellness, as consumer behaviors shift toward lower calorie consumption and health-conscious choices.
• The FDA recently announced the end of a GLP-1 drug shortage, limiting compounding pharmacies' ability to produce cheaper alternatives, raising concerns about affordability and accessibility.
• Critics argue that these drugs, while transformative, exacerbate societal fatphobia, increasing pressure on individuals to conform to thinness standards and undermining body positivity efforts.